Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation

被引：581

作者：

Kotton, Camille N. ^{[1
]}

Kumar, Deepali ^{[2
]}

Caliendo, Angela M. ^{[3
]}

Asberg, Anders ^{[4
]}

Chou, Sunwen ^{[5
]}

Danziger-Isakov, Lara ^{[6
]}

Humar, Atul ^{[7
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Brown Univ, Alpert Med Sch Brown, Providence, RI 02912 USA

[4] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway

[5] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA

[7] Univ Alberta, Dept Med, Alberta Transplant Inst, Edmonton, AB, Canada

来源：

TRANSPLANTATION | 2013年 / 96卷 / 04期

关键词：

Cytomegalovirus; CMV; Ganciclovir; Prevention; Prophylaxis; Resistance; Treatment; Valganciclovir; T-CELL RESPONSES; DRUG-RESISTANT CYTOMEGALOVIRUS; EPSTEIN-BARR-VIRUS; EXTENDED VALGANCICLOVIR PROPHYLAXIS; BRONCHIOLITIS OBLITERANS SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; HEPATIC-ARTERY THROMBOSIS; MANNOSE-BINDING LECTIN; VS. ORAL GANCICLOVIR; LONG-TERM RECIPIENT;

D O I：

10.1097/TP.0b013e31829df29d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ transplantation, resulting in significant morbidity, graft loss, and adverse outcomes. Management of CMV varies considerably among transplant centers but has been become more standardized by publication of consensus guidelines by the Infectious Diseases Section of The Transplantation Society. An international panel of experts was reconvened in October 2012 to revise and expand evidence and expert opinion-based consensus guidelines on CMV management, including diagnostics, immunology, prevention, treatment, drug resistance, and pediatric issues. The following report summarizes the recommendations.

引用

页码：333 / 360

页数：28

共 272 条

[81] Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients:: A prospective, randomized, controlled, open-label trial. [J].

Gerna, G ;

Baldanti, F ;

Lilleri, D ;

Parea, M ;

Torsellini, M ;

Castiglioni, B ;

Vitulo, P ;

Pellegrini, C ;

Viganò, M ;

Grossi, P ;

Revello, MG .

TRANSPLANTATION, 2003, 75 (07) :1012-1019

[82] Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients [J].

Gerna, G. ;

Lilleri, D. ;

Rognoni, V. ;

Agozzino, M. ;

Meloni, F. ;

Oggionni, T. ;

Pellegrini, C. ;

Arbustini, E. ;

D'Armini, A. M. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1142-1150

[83] Human cytomegalovirus resistance to antiviral drugs [J].

Gilbert, C ;

Boivin, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :873-883

[84] Hypogammaglobulinemia in lung transplant recipients [J].

Goldfarb, NS ;

Avery, RK ;

Goormastic, M ;

Mehta, AC ;

Schilz, R ;

Smedira, N ;

Pien, L ;

Haug, MT ;

Gordon, SH ;

Hague, LK ;

Dresing, JM ;

Evans-Walker, T ;

Maurer, JR .

TRANSPLANTATION, 2001, 71 (02) :242-246

[85] The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase [J].

Goldner, Thomas ;

Hewlett, Guy ;

Ettischer, Nicole ;

Ruebsamen-Schaeff, Helga ;

Zimmermann, Holger ;

Lischka, Peter .

JOURNAL OF VIROLOGY, 2011, 85 (20) :10884-10893

[86] Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation [J].

Gómez, E ;

Laurés, A ;

Baltar, JM ;

Melón, S ;

Díez, B ;

de Oña, M .

TRANSPLANTATION PROCEEDINGS, 2005, 37 (09) :3760-3763

[87] What Is The True Significance of Donor-Related Cytomegalovirus Transmission in the Setting of Facial Composite Tissue Allotransplantation? [J].

Gordon, C. R. ;

Abouhassan, W. ;

Avery, R. K. .

TRANSPLANTATION PROCEEDINGS, 2011, 43 (09) :3516-3520

[88] Cytomegalovirus and Other Infectious Issues Related to Face Transplantation: Specific Considerations, Lessons Learned, and Future Recommendations [J].

Gordon, Chad R. ;

Avery, Robin K. ;

Abouhassan, William ;

Siemionow, Maria .

PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 127 (04) :1515-1523

[89] CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients [J].

Green, M. ;

Michaels, M. G. ;

Katz, B. Z. ;

Burroughs, M. ;

Gerber, D. ;

Shneider, B. L. ;

Newell, K. ;

Rowe, D. ;

Reyes, J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) :1906-1912

[90] Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children [J].

Green, M ;

Kaufmann, M ;

Wilson, J ;

Reyes, J .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (06) :1344-1349

← 4 5 6 7 8 9 10 11 12 13 →